Disturbance to nuclear transport caused by protein aggregation has been implicated in the pathology of ALS and FTD.
Browsing: Amyotrophic lateral sclerosis
As we begin a new year on Neuro Central, we’re taking this opportunity to look back at some of the highlights across neuroscience and neurology in 2017.
Discover more about how advances in amyotrophic lateral sclerosis research are influencing approaches to patient care in this review from Neurodegenerative Disease Management
Researchers from the University of Missouri have discovered an enzyme pathway that may present a potential therapeutic target for ALS and, possibly, other neurological diseases including stroke.
The California Institute for Regenerative Medicine (CIRM) announces that it is investing $15.9 million in a therapy to tackle ALS.
Researchers discover that the drug, pyrimethamine, may reduce disease progression in patients with inherited amyotrophic lateral sclerosis (ALS).
Participants in the top 25% for estimated annual mercury intake had a twofold higher risk of developing amyotrophic lateral sclerosis.
Utilizing data from a study into amyotrophic lateral sclerosis (ALS) progression, a team of researchers has examined associations between nutritional intake, function and respiratory function.
Researchers from the Ben-Gurion University of the Negev (Beersheba, Israel) have identified a novel molecular mechanism that could lead to the development of new therapies for amyotrophic lateral sclerosis.
Identification of Apo B48 and other novel biomarkers in amyotrophic lateral sclerosis patient fibroblasts
This study utilized SILAC proteomic analysis of human ALS patient and population control fibroblasts to discover proteins that are differentially regulated in ALS and may serve as useful biomarkers.